Logo image of BFRI

BIOFRONTERA INC (BFRI) Stock Fundamental Analysis

NASDAQ:BFRI - Nasdaq - US09077D2099 - Common Stock - Currency: USD

0.8822  +0.03 (+3.67%)

After market: 0.9 +0.02 (+2.02%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BFRI. BFRI was compared to 194 industry peers in the Pharmaceuticals industry. BFRI may be in some trouble as it scores bad on both profitability and health. BFRI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BFRI had negative earnings in the past year.
BFRI had a negative operating cash flow in the past year.
BFRI had negative earnings in each of the past 5 years.
In the past 5 years BFRI always reported negative operating cash flow.
BFRI Yearly Net Income VS EBIT VS OCF VS FCFBFRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

BFRI has a Return On Assets of -69.48%. This is in the lower half of the industry: BFRI underperforms 68.04% of its industry peers.
BFRI has a Return On Equity of -2457.36%. This is amonst the worse of the industry: BFRI underperforms 83.51% of its industry peers.
Industry RankSector Rank
ROA -69.48%
ROE -2457.36%
ROIC N/A
ROA(3y)-51.23%
ROA(5y)-54.01%
ROE(3y)-274.43%
ROE(5y)-268.87%
ROIC(3y)N/A
ROIC(5y)N/A
BFRI Yearly ROA, ROE, ROICBFRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

BFRI has a better Gross Margin (53.26%) than 64.95% of its industry peers.
In the last couple of years the Gross Margin of BFRI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BFRI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y-0.95%
BFRI Yearly Profit, Operating, Gross MarginsBFRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

0

2. Health

2.1 Basic Checks

BFRI does not have a ROIC to compare to the WACC, probably because it is not profitable.
BFRI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BFRI has been increased compared to 5 years ago.
The debt/assets ratio for BFRI is higher compared to a year ago.
BFRI Yearly Shares OutstandingBFRI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
BFRI Yearly Total Debt VS Total AssetsBFRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -10.59, we must say that BFRI is in the distress zone and has some risk of bankruptcy.
BFRI has a Altman-Z score of -10.59. This is in the lower half of the industry: BFRI underperforms 70.62% of its industry peers.
A Debt/Equity ratio of 8.99 is on the high side and indicates that BFRI has dependencies on debt financing.
BFRI has a worse Debt to Equity ratio (8.99) than 83.51% of its industry peers.
Industry RankSector Rank
Debt/Equity 8.99
Debt/FCF N/A
Altman-Z -10.59
ROIC/WACCN/A
WACC19.19%
BFRI Yearly LT Debt VS Equity VS FCFBFRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 1.40 indicates that BFRI should not have too much problems paying its short term obligations.
BFRI has a Current ratio of 1.40. This is in the lower half of the industry: BFRI underperforms 71.65% of its industry peers.
A Quick Ratio of 0.80 indicates that BFRI may have some problems paying its short term obligations.
BFRI has a worse Quick ratio (0.80) than 82.99% of its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 0.8
BFRI Yearly Current Assets VS Current LiabilitesBFRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

6

3. Growth

3.1 Past

BFRI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.43%, which is quite impressive.
The Revenue has grown by 14.25% in the past year. This is quite good.
BFRI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.35% yearly.
EPS 1Y (TTM)89.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.68%
Revenue 1Y (TTM)14.25%
Revenue growth 3Y15.69%
Revenue growth 5Y7.35%
Sales Q2Q%8.54%

3.2 Future

The Earnings Per Share is expected to grow by 28.02% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 24.02% on average over the next years. This is a very strong growth
EPS Next Y75.6%
EPS Next 2Y39.63%
EPS Next 3Y28.02%
EPS Next 5YN/A
Revenue Next Year4.02%
Revenue Next 2Y10.36%
Revenue Next 3Y19.18%
Revenue Next 5Y24.02%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BFRI Yearly Revenue VS EstimatesBFRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
BFRI Yearly EPS VS EstimatesBFRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BFRI. In the last year negative earnings were reported.
Also next year BFRI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BFRI Price Earnings VS Forward Price EarningsBFRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BFRI Per share dataBFRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as BFRI's earnings are expected to grow with 28.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.63%
EPS Next 3Y28.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BFRI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOFRONTERA INC

NASDAQ:BFRI (7/18/2025, 8:00:01 PM)

After market: 0.9 +0.02 (+2.02%)

0.8822

+0.03 (+3.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners15.84%
Inst Owner Change0%
Ins Owners3.41%
Ins Owner Change0%
Market Cap8.34M
Analysts82.5
Price Target6.5 (636.79%)
Short Float %2.53%
Short Ratio0.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-497.35%
Min EPS beat(2)-880.39%
Max EPS beat(2)-114.32%
EPS beat(4)1
Avg EPS beat(4)-229.03%
Min EPS beat(4)-880.39%
Max EPS beat(4)93.63%
EPS beat(8)1
Avg EPS beat(8)-147.46%
EPS beat(12)3
Avg EPS beat(12)-91.41%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.73%
Min Revenue beat(2)-20.19%
Max Revenue beat(2)-15.26%
Revenue beat(4)0
Avg Revenue beat(4)-13.38%
Min Revenue beat(4)-20.19%
Max Revenue beat(4)-6.36%
Revenue beat(8)1
Avg Revenue beat(8)-11.97%
Revenue beat(12)1
Avg Revenue beat(12)-9.29%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)18.6%
PT rev (3m)-39.29%
EPS NQ rev (1m)3.45%
EPS NQ rev (3m)-27.27%
EPS NY rev (1m)13.1%
EPS NY rev (3m)-30.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.79%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.22
P/FCF N/A
P/OCF N/A
P/B 17.78
P/tB 19.03
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-1.17
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS4.02
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.48%
ROE -2457.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.26%
FCFM N/A
ROA(3y)-51.23%
ROA(5y)-54.01%
ROE(3y)-274.43%
ROE(5y)-268.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y-0.95%
F-Score4
Asset Turnover2.29
Health
Industry RankSector Rank
Debt/Equity 8.99
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.86%
Cap/Sales 0.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 0.8
Altman-Z -10.59
F-Score4
WACC19.19%
ROIC/WACCN/A
Cap/Depr(3y)7.65%
Cap/Depr(5y)4.96%
Cap/Sales(3y)0.1%
Cap/Sales(5y)0.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.68%
EPS Next Y75.6%
EPS Next 2Y39.63%
EPS Next 3Y28.02%
EPS Next 5YN/A
Revenue 1Y (TTM)14.25%
Revenue growth 3Y15.69%
Revenue growth 5Y7.35%
Sales Q2Q%8.54%
Revenue Next Year4.02%
Revenue Next 2Y10.36%
Revenue Next 3Y19.18%
Revenue Next 5Y24.02%
EBIT growth 1Y27.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.78%
OCF growth 3YN/A
OCF growth 5YN/A